Eventration and central tendon defect of diaphragm give way to herniate abdominal contents into the thorax in congenital diaphragmatic hernia (CDH). Its incidence is approximately 1 in 3000 live births with a reported mortality of 40% - 62% depending on the associated major malformation (
1). As a consequence of underdevelopment of the lung parenchyma, due to herniated abdominal contents in thorax, abnormal pulmonary vasculature growth may occur resulting in increased pulmonary vascular resistance and pulmonary hypertension (PAH). A recent study in collaboration with the CDH registry reported a 41% prevalence of bronchopulmonary dysplasia (BPD) in survivors of CDH, about one-third of the cases are associated with cardio-vascular malformations, and lesser proportions have skeletal, neural, genitourinary, gastrointestinal or other defects (
2). BPD associated with pulmonary hypertension carries a higher risk of pulmonary morbidity. It is a standard practice to ventilate such neonates electively in postoperative period to recruit the alveoli and maintain oxygenation (
3). Perioperative sympathetic stimulation due to pain, response to endotracheal tube, hypoxia, hypercarbia and hypervolemia will aggravate PAH and adversely affect the postoperative outcomes.
Dexmedetomidine has predictable sympatholytic, analgesic, hypnotic and anxiolytic effects without respiratory depression and its pharmacologic effect is mediated through post-synaptic α-2 adrenergic receptors present in medullary vasomotor center, locus ceruleus and dorsal horn of spinal cord (
4). It is safe even in doses high enough to cause unresponsiveness (
5). In adult intensive care units (ICUs), it is helpful to reduce traditional sedative/analgesic use while still allowing for a calm, comfortable and cooperative state (
6). In adults with pulmonary hypertension undergoing mitral valve replacement, dexmedetomidine effectively attenuated the increase in mean arterial pressure (MAP), pulmonary arterial pressure (PAP) and pulmonary capillary wedge pressure (PCWP) (
7,
8). Effects of dexmedetomidine 0.62 μg/kg loading dose followed by an infusion of 0.5 μg/kg/hour on PAP and pulmonary vascular resistance (PVR) were evaluated in a cohort of 22 pediatric patients following the congenital heart disease surgery using echocardiographic analysis of tricuspid regurgitant velocity showed reduction in pulmonary artery systolic pressure as well as pulmonary artery systolic pressure to systemic systolic pressure ratio (
9). Additionally, anecdotal success is also reported with the use of dexmedetomidine for sedation in high risk patients with pulmonary hypertension (
10-
12). Based on its efficacy in adults, it is explored as an alternative or adjunct to benzodiazepines and opioids in the pediatric intensive care setting (
13). Neonatal experience with dexmedetomidine is predominately in the form of case series and small reports, mainly focusing on its short term or procedural use. In neonatal congenital diaphragmatic hernia associated with pulmonary artery hypertension, perioperative use of dexmedetomidine is expected to result in stable hemodynamics, smooth elective mechanical ventilation and decrease in PAP. Thus this study of extended dexmedetomidine infusion was planned in neonatal corrective surgery of CDH with PAH in an attempt to assess its effect on perioperative hemodynamics and oxygen saturation.